While there are no current therapies in preclinical or clinical trials targeting TREM2 in the context of TB, AL002, a humanized monoclonal TREM2 antibody currently in a phase 2 clinical trial, has been reported to be a promising candidate for Alzheimer’s disease therapy (73). Here, TREM2 is linked to early-onset autosomal dominant Alzheimer disease.